Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:fce88d640556b12095345977d5c2fd69]
Margaret L. MacMillan, M.D. [clinicaltrials_resource:03c397b50feb8975b5b7e88d737cf2ba]Michael R. Verneris, M.D. [clinicaltrials_resource:04d0444fbc137ee019ac0a9d73c7e549]Antonio Pellicer, MDPhD [clinicaltrials_resource:04d4442faff5f7e35e194ccdd801cc11]Sharon S. Allen, M.D., Ph.D. [clinicaltrials_resource:081c0ea4f1e55593f25d95da03e94929]Bevan Yueh, MD, MPH [clinicaltrials_resource:0980311091b8077e1d95f87dc36714ea]Daniel Weisdorf, M.D. [clinicaltrials_resource:0a8f750dfcce9cd0542bf45d9f36f1bc]Margaret MacMillan, MD [clinicaltrials_resource:0ad461edf073cff8a34636efe1bb798a]Edward Cheng, MD [clinicaltrials_resource:0dce01b2588f0a674b5e8a96e774891c]Sharon S. Allen, M.D. [clinicaltrials_resource:0e6b5e703067829119f13762f5ff21d6]Marcie Tomblyn, MD, MS [clinicaltrials_resource:10a208b9ed25d36726805ae76511640a]Peter Argenta, M.D. [clinicaltrials_resource:139b5e457b57162054085ba0d61b73b3]Margaret MacMillan, MD [clinicaltrials_resource:147a7ecc77be53ff1163fc05eb1a0a11]Abraham Kroon, MD, PhD [clinicaltrials_resource:1526800ff7e961797416facd992a3b32]Weston Miller, M.D. [clinicaltrials_resource:1530c57476d2a3529a533eb088f23841]Bevan Yueh, MD, MPH [clinicaltrials_resource:1593b9a89faf951e7795e3462aed234b]Priya Kumar, MD [clinicaltrials_resource:15ff4dc75077cde05e930c50f9e37c81]Amy Jonson, MD [clinicaltrials_resource:187365dc8983a9fcfec8e2138b59bb0d]Sarah Cooley, M.D. [clinicaltrials_resource:18ef62e4e8dd0d0200bca9fc0b622be1]Sarah Cooley, M.D. [clinicaltrials_resource:19c6f7ffb58fa2c049d7d3b88700fb30]Levi S. Downs, MD [clinicaltrials_resource:1acefb51ca1b96c48674503920ebc5ad]Bevan Yueh, MD, MPH [clinicaltrials_resource:1b6159e6ad183c6b0b0ae87c9dcfe0b2]Daniel J. Weisdorf, MD [clinicaltrials_resource:1c576de4d9827da7ce64b8d2f521cea0]Rahel Ghebre, M.D. [clinicaltrials_resource:1d65a8a10052088015cbfdbbf131c6d1]Curtis Corum, Ph.D. [clinicaltrials_resource:1db3557b13a10d2b4716002f37fc1df4]John E. Wagner, MD [clinicaltrials_resource:1f0f8464b381d7b7944e478bc0110528]Kristin E. Anderson, Ph.D. [clinicaltrials_resource:1f2fe92274f93addfd080df1142f293a]Michael Verneris, M.D. [clinicaltrials_resource:1f3a17cc8ef597766de8d35b3ecea8b7]Melissa A. Geller, M.D. [clinicaltrials_resource:1f4e73c0d8a3eddbde90cf4f1f07262c]Daniel Weisdorf, M.D. [clinicaltrials_resource:2027c8336ad4f36236e9385e6a50571c]Sarah Cooley, MD [clinicaltrials_resource:22bb486fc79a91d1801e48f70c1cc9c6]Sharon S. Allen, M.D. [clinicaltrials_resource:23fcb2497b3f4052421823947e00cce2]Dorothy Hatsukami, M.D. [clinicaltrials_resource:265b4702ca901f38aa52fe5a82fb827c]Douglas Yee, MD [clinicaltrials_resource:2ab9ed2d3cb8b9edce250b43ee926a8a]Michael R. Verneris, M.D. [clinicaltrials_resource:2bd3ec828c48b6d32b677b1157aeefc6]Erica Warlick, MD [clinicaltrials_resource:2cffb815b677cd808617640b27349bc1]John E. Wagner, MD [clinicaltrials_resource:2e44d3f1e8132b5b863dd4dfc34ca447]Margaret MacMillan, MD [clinicaltrials_resource:2e52609207e39cf19322324b9863c0ad]Margaret L. MacMillan, MD [clinicaltrials_resource:2f188668cdda36af23a8be08df11847c]Dorothy Hatsukami, M.D. [clinicaltrials_resource:3051e01e86d0863da45738faec7cef36]Todd M. Tuttle, MD [clinicaltrials_resource:307f2bbcc507e37daeb4c35e1baa3634]
affiliation [clinicaltrials_vocabulary:affiliation]
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer [clinicaltrials:NCT00005993]Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease [clinicaltrials:NCT00005998]Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors [clinicaltrials:NCT00095160]clinicaltrials:NCT00176852clinicaltrials:NCT00258362clinicaltrials:NCT00276159clinicaltrials:NCT00287911Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [clinicaltrials:NCT00290628]Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer [clinicaltrials:NCT00290641]clinicaltrials:NCT00319748clinicaltrials:NCT00352118Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer [clinicaltrials:NCT00365287]clinicaltrials:NCT00392782clinicaltrials:NCT00400803clinicaltrials:NCT00625729clinicaltrials:NCT00680667clinicaltrials:NCT00691132clinicaltrials:NCT00818649clinicaltrials:NCT00869323clinicaltrials:NCT00889408clinicaltrials:NCT00903630clinicaltrials:NCT00963872clinicaltrials:NCT01009437clinicaltrials:NCT01012362clinicaltrials:NCT01056601clinicaltrials:NCT01288222clinicaltrials:NCT01312818clinicaltrials:NCT01343368clinicaltrials:NCT01593670clinicaltrials:NCT01639456clinicaltrials:NCT02118285clinicaltrials:NCT02118311Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome [clinicaltrials:NCT02156674]
collaborator [clinicaltrials_vocabulary:collaborator]
Vaccination With Tetanus and KLH to Assess Immune Responses. [clinicaltrials:NCT00000105]clinicaltrials:NCT00003926clinicaltrials:NCT00005984Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma [clinicaltrials:NCT00005985]Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00005986]Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma [clinicaltrials:NCT00005987]Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer [clinicaltrials:NCT00005993]Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease [clinicaltrials:NCT00005998]Bone Marrow Transplantation in Treating Patients With Leukemia [clinicaltrials:NCT00006451]Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors [clinicaltrials:NCT00095160]Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia [clinicaltrials:NCT00167167]clinicaltrials:NCT00167180clinicaltrials:NCT00167206clinicaltrials:NCT00167219clinicaltrials:NCT00176826clinicaltrials:NCT00176839clinicaltrials:NCT00176852Stem Cell Transplant for Immunologic or Histiocytic Disorders [clinicaltrials:NCT00176865]clinicaltrials:NCT00176878Stem Cell Transplant w/Laronidase for Hurler [clinicaltrials:NCT00176891]clinicaltrials:NCT00176904clinicaltrials:NCT00176917clinicaltrials:NCT00176930clinicaltrials:NCT00177047clinicaltrials:NCT00258362clinicaltrials:NCT00258427clinicaltrials:NCT00262951clinicaltrials:NCT00265863clinicaltrials:NCT00274846clinicaltrials:NCT00276159clinicaltrials:NCT00281827clinicaltrials:NCT00287859Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer [clinicaltrials:NCT00287885]clinicaltrials:NCT00287911Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [clinicaltrials:NCT00290628]Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer [clinicaltrials:NCT00290641]clinicaltrials:NCT00290654clinicaltrials:NCT00295880clinicaltrials:NCT00303667clinicaltrials:NCT00303719
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Levi Downs, Jr, MD, Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:0cd229b69dc9aaf46ec6fba65df002f3]Arkadiusz Dudek, M.D., Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:1cd5a186421f623077ba1f7c94f2c988]Sarah Cooley, M.D., Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:550865280be2aa9faff068e07210e150]John Wagner, M.D., Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:5686f14d144f8d8b9332383430a53deb]Catherine Verfaille, MD, Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:741a394979516fc309ada95d530b0ea0]John Perentesis, MD, Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:b12c962c0b75ec546b8d2d4f97fecbbf]Linda Burns, M.D., Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:b47d67774985e86810dc4127a98263a8]Melissa Geller, M.D., Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:bc83259c4279c7e6759f94192fc12b9e]Todd M. Tuttle, MD, Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:c80c15a3f572d535a7e20bd94ab6f742]MacMillan, Margaret L., MD, Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:e489de498da7f6302f9fd6fa0a62f1a9]Chinsoo Cho MD, Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:e70b9f6d4f5e9627916aa019287ba8fb]Todd Tuttle, MD, Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:f438a2cbb45ea80bd4208108d48b64b9]Jeffrey Miller, M.D., Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:f570de3ca050b861f42c72ffecd4c2e8]Jeffrey Miller, MD, Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:fdabe6ff24516bb5d487e70d83fbd0fb]
organization [clinicaltrials_vocabulary:organization]
Vaccination With Tetanus and KLH to Assess Immune Responses. [clinicaltrials:NCT00000105]clinicaltrials:NCT00003926clinicaltrials:NCT00005984Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma [clinicaltrials:NCT00005985]Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00005986]Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma [clinicaltrials:NCT00005987]Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer [clinicaltrials:NCT00005993]Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease [clinicaltrials:NCT00005998]Bone Marrow Transplantation in Treating Patients With Leukemia [clinicaltrials:NCT00006451]Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors [clinicaltrials:NCT00095160]Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia [clinicaltrials:NCT00167167]clinicaltrials:NCT00167180clinicaltrials:NCT00167206clinicaltrials:NCT00167219clinicaltrials:NCT00176826clinicaltrials:NCT00176839clinicaltrials:NCT00176852Stem Cell Transplant for Immunologic or Histiocytic Disorders [clinicaltrials:NCT00176865]clinicaltrials:NCT00176878Stem Cell Transplant w/Laronidase for Hurler [clinicaltrials:NCT00176891]clinicaltrials:NCT00176904clinicaltrials:NCT00176917clinicaltrials:NCT00176930clinicaltrials:NCT00177047clinicaltrials:NCT00258362clinicaltrials:NCT00258427clinicaltrials:NCT00262951clinicaltrials:NCT00265863clinicaltrials:NCT00274846clinicaltrials:NCT00276159clinicaltrials:NCT00281827clinicaltrials:NCT00287859Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer [clinicaltrials:NCT00287885]clinicaltrials:NCT00287911Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [clinicaltrials:NCT00290628]Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer [clinicaltrials:NCT00290641]clinicaltrials:NCT00290654clinicaltrials:NCT00295880clinicaltrials:NCT00303667clinicaltrials:NCT00303719
source [clinicaltrials_vocabulary:source]
Masonic Cancer Center, University of Minnesota [clinicaltrials_resource:fce88d640556b12095345977d5c2fd69]
Bio2RDF identifier
fce88d640556b12095345977d5c2fd69
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:fce88d640556b12095345977d5c2fd69
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:fce88d640556b12095345977d5c2fd69
title
Masonic Cancer Center, University of Minnesota
@en
type
label
Masonic Cancer Center, Univers ...... 88d640556b12095345977d5c2fd69]
@en